A5061209536- Cutaneous Melanoma Detection and Management
- CAR-T cell therapy research
- Melanoma and MAPK Pathways
- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- Nonmelanoma Skin Cancer Studies
- Polyomavirus and related diseases
- Sarcoma Diagnosis and Treatment
- Antenna Design and Analysis
- Computational Drug Discovery Methods
- Full-Duplex Wireless Communications
- Cancer Genomics and Diagnostics
- Cutaneous lymphoproliferative disorders research
- Bacteriophages and microbial interactions
- Immune Cell Function and Interaction
- Advanced Biosensing Techniques and Applications
- Plant Virus Research Studies
- Brain Metastases and Treatment
- Monoclonal and Polyclonal Antibodies Research
- Cancer and Skin Lesions
- Cell Image Analysis Techniques
- vaccines and immunoinformatics approaches
- Heat shock proteins research
- Vascular Tumors and Angiosarcomas
- Cervical Cancer and HPV Research
Moffitt Cancer Center
2016-2025
University of South Florida
2016-2025
Richard M. Schulze Family Foundation
2021-2022
Melanoma Institute Australia
2011-2022
Norfolk and Norwich University Hospital
2022
Bristol-Myers Squibb (Germany)
2008-2020
Roche (Switzerland)
2020
Novartis (Switzerland)
2020
Hospital of the University of Pennsylvania
2020
University of Tampa
2020
To revise the staging system for cutaneous melanoma on basis of data from an expanded American Joint Committee Cancer (AJCC) Melanoma Staging Database.The recommendations were made a multivariate analysis 30,946 patients with stages I, II, and III 7,972 stage IV to clarify TNM classifications grouping criteria.Findings new definitions include following: (1) in localized melanoma, tumor thickness, mitotic rate (histologically defined as mitoses/mm(2)), ulceration most dominant prognostic...
Answer questions and earn CME/CNE To update the melanoma staging system of American Joint Committee on Cancer (AJCC) a large database was assembled comprising >46,000 patients from 10 centers worldwide with stages I, II, III diagnosed since 1998. Based analyses this new database, existing seventh edition AJCC stage IV contemporary clinical trial data, Melanoma Expert Panel introduced several important changes to Tumor, Nodes, Metastasis (TNM) classification grouping criteria. Key in eighth...
PURPOSE: Pivotal trial E1684 of adjuvant high-dose interferon alfa-2b (IFNα2b) therapy in high-risk melanoma patients demonstrated a significant relapse-free and overall survival (RFS OS) benefit compared with observation (Obs). PATIENTS AND METHODS: A prospective, randomized, three-arm, intergroup evaluated the efficacy IFNα2b (HDI) for 1 year low-dose (LDI) 2 years versus Obs (stage IIB III) RFS OS end points. RESULTS: total 642 were enrolled (608 eligible), whom majority (75%) had nodal...
PURPOSE: Vaccine alternatives to high-dose interferon alfa-2b therapy (HDI), the current standard adjuvant for high-risk melanoma, are of interest because toxicity associated with HDI. The GM2 ganglioside is a well-defined melanoma antigen, and anti-GM2 antibodies have been improved prognosis. We conducted prospective, randomized, intergroup trial evaluate efficacy HDI 1 year versus vaccination conjugated keyhole limpet hemocyanin administered QS-21 (GMK) 96 weeks (weekly × 4 then every 12...
Objective tumor response rates observed in phase II trials for metastatic melanoma have historically not provided a reliable indicator of meaningful survival benefits. To facilitate using overall (OS) or progression-free (PFS) as an endpoint future trials, we evaluated historical data from cooperative group to attempt develop benchmarks OS and PFS reference points trials.Individual-level trial-level were obtained patients enrolled onto 42 (70 trial arms) that completed accrual the years 1975...
Gene-based immunotherapy for cancer is limited by the lack of safe, efficient, reproducible, and titratable delivery methods. Direct injection DNA into tissue, although safer than viral vectors, suffers from low gene transfer efficiency. In vivo electroporation, in preclinical models, significantly enhances efficiency while retaining safety advantages plasmid DNA.A phase I dose escalation trial interleukin (IL)-12 electroporation was carried out patients with metastatic melanoma. Patients...
Abstract Purpose: Nearly 2000 patients with stage IIB and III melanoma have participated in four multicenter, randomized trials, conducted by the Eastern Cooperative Oncology Group Intergroup, investigating adjuvant high-dose IFN-α 2b therapy. The objectives of this study were to update analyses each individual trial analyze prognostic factors treatment effects based on pooled data. Experimental Design: Survival disease status updated April 2001. Analysis using optimized statistical models...
This study addresses the role of PTEN loss in intrinsic resistance to BRAF inhibitor PLX4720. Immunohistochemical staining a tissue array covering all stages melanocytic neoplasia (n = 192) revealed expression be lost >10% melanoma cases. Although status did not predict for sensitivity growth inhibitory effects PLX4720, it was predictive apoptosis, with only limited cell death observed melanomas lacking (PTEN-). Mechanistically, PLX4720 found stimulate AKT signaling PTEN- but PTEN+ lines....
Whether pembrolizumab given both before surgery (neoadjuvant therapy) and after (adjuvant therapy), as compared with adjuvant therapy alone, would increase event-free survival among patients resectable stage III or IV melanoma is unknown.In a phase 2 trial, we randomly assigned clinically detectable, measurable IIIB to IVC that was amenable surgical resection three doses of neoadjuvant pembrolizumab, surgery, 15 (neoadjuvant-adjuvant group) followed by (200 mg intravenously every 3 weeks for...
To determine the survival rates and independent predictors of using a contemporary international cohort patients with stage III melanoma.
Purpose The aim of this study was to assess the independent prognostic value primary tumor mitotic rate compared with other clinical and pathologic features stages I II melanoma. Methods From American Joint Committee on Cancer (AJCC) melanoma staging database, information extracted for 13,296 patients disease who had data available. Results Survival times declined as increased. Ten-year survival ranged from 93% whose tumors 0 mitosis/mm 2 48% those ≥ 20/mm (P < .001). Mean number...
Purpose Phase II trials with biochemotherapy (BCT) have shown encouraging response rates in metastatic melanoma, and meta-analyses one phase III trial suggested a survival benefit. In an effort to determine the relative efficacy of BCT compared chemotherapy alone, was performed within United States Intergroup. Patients Methods were randomly assigned receive cisplatin, vinblastine, dacarbazine (CVD) either alone or concurrent interleukin-2 interferon alfa-2b (BCT). Treatment cycles repeated...
Resistance to BRAF inhibitors is an emerging problem in the melanoma field. Strategies prevent and overcome resistance are urgently required. The dynamics of cell signalling, BrdU incorporation cell-cycle entry after inhibition was measured using flow cytometry western blot. ability combined BRAF/MEK emergence demonstrated by apoptosis colony formation assays 3D organotypic culture. led a rapid recovery phospho-ERK (pERK) signalling. Although most cells remained growth arrested presence...
Indications for sentinel lymph node biopsy (SLNB) thin melanoma are continually evolving. We present a large multi-institutional study to determine factors predictive of (SLN) metastasis in melanoma.Retrospective review the Sentinel Lymph Node Working Group database from 1994 2012 identified 1,250 patients who had an SLNB and melanomas (≤ 1 mm). Clinicopathologic characteristics were correlated with SLN status outcome.SLN metastases detected 65 (5.2%) patients. On univariable analysis, rates...
Background: Merkel cell carcinoma (MCC) has a high risk of recurrence after initial surgical therapy. Adjuvant radiation therapy (RT) and chemotherapy may be used to reduce the locoregional systemic recurrence, respectively, but there are conflicting data regarding their impact on survival. We performed retrospective analysis MCC cases from National Cancer Data Base (NCDB) assess whether adjuvant was associated with differences in Methods: Six thousand nine hundred eight patients staging,...
PURPOSE Combination of antiprogrammed cell death protein-1 (PD-1) plus anti–cytotoxic T-cell lymphocyte-4 (anti-CTLA-4) immunotherapy shows greater response rates (RRs) than anti-PD-1 antibody alone in melanoma, but RR after initial and programmed ligand-1 (PD-L1) progression awaits robust investigation. Anti-CTLA-4 anti-PD-1/L1 has a historical 13%. We report the results first prospective clinical trial evaluating ipilimumab 1 mg/kg pembrolizumab following on immunotherapy. METHODS Patients...
PURPOSE Phase III adjuvant trials have reported significant benefits in both relapse-free survival (RFS) and overall (OS) for high-dose interferon alfa (HDI) ipilimumab at 10 mg/kg (ipi10). E1609 evaluated the safety efficacy of 3 (ipi3) ipi10 versus HDI. PATIENTS AND METHODS was a phase trial patients with resected cutaneous melanoma (American Joint Committee on Cancer 7th edition stage IIIB, IIIC, M1a, or M1b). It had 2 coprimary end points: OS RFS. A 2-step hierarchic approach first ipi3...
Melanoma brain metastases (MBM) and leptomeningeal melanoma (LMM) are two different manifestations of CNS metastasis. Here, we used single-cell RNA sequencing (scRNA-seq) to define the immune landscape MBM, LMM, skin metastases.scRNA-seq was undertaken on 43 patient specimens, including 8 metastases, 14 19 serial LMM specimens. Detailed cell type curation performed, landscapes were mapped, key results validated by IHC flow cytometry. Association analyses identify subsets correlated with...